A Single Arm, Multicenter Clinical Study of High-dose Furmonertinib in First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases
Latest Information Update: 26 Sep 2024
At a glance
- Drugs Firmonertinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 19 Sep 2024 Planned primary completion date changed from 31 Jul 2024 to 31 Dec 2024.
- 24 May 2022 New trial record